Evaluate the Efficacy and Safety of KK8398 in Patients With Achondroplasia（AOBA Study）
← catalyst calendarNCT06926491 · readout in 1,016 d
Sponsored by Kyowa Kirin Co., Ltd. (industry) · 4151.T — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
6estimated
Sites
9
Country
Japan
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-12-01 | actual | When the study began enrolling |
| Primary completion | 2029-05-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2031-05-31 | estimated | The whole study's end, after follow-up |
| First posted | 2025-04-13 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-04-29 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Achondroplasia
Intervention
- Drug: KK8398
Primary outcome
what the primary-completion date above is the date OFChange from baseline in annualized height velocity
measured Pre-dose, Week 52
Permalink · 4151.T's whole pipeline · Catalyst calendar · Every registered study · What changed